BRAIN Biotech AG (HAM:BNN) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BNN BRAIN Biotech AG HAM:BNN
69 GF Score
Price €2.78
GF Value €2.49
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG FFO?

FFO (Funds from operations) only applies to REITs.

HAM:BNN
69GF Score
BRAIN Biotech AG HAM:BNN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.78 is trading 11.6% above its estimated GF Value™ of €2.49. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

  • FFO:
  • GF Value™: €2.49 vs. price of €2.78 (11.6% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
69GF Score

Get the complete analysis for HAM:BNN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.78
Price
€2.49
GF Value